Zafgen to Present Two Late-Breaking Abstracts for ZGN-1061 at the American Diabetes Association 77th Scientific Sessions
June 06, 2017 16:05 ET
|
Zafgen, Inc.
-Clinical Abstract will provide full data set from ZGN-1061 Phase 1 Clinical Trial- -Preclinical Abstract will present results for ZGN-1061 on glycemic control, weight loss and safety profile- ...
Zafgen Reports First Quarter 2017 Financial Results
May 09, 2017 16:05 ET
|
Zafgen, Inc.
-ZGN-1061 Phase 1 Data Support Continued Development; On Track to Initiate Phase 2 Clinical Trial in Patients with Type 2 Diabetes in Second Half of This Year- BOSTON, May 09, 2017 (GLOBE NEWSWIRE)...
Zafgen Announces Positive Topline Phase 1 Data for ZGN-1061, a Second Generation MetAP2 Inhibitor
May 04, 2017 16:05 ET
|
Zafgen, Inc.
- Clinical Trial Shows Weight Loss Trends of Up to One Pound Per Week and an Early Favorable Safety and Tolerability Profile - - Improvements in Metabolic Parameters and Trends for Weight Loss...
Zafgen Reports Fourth Quarter and Full Year 2016 Financial Results
March 09, 2017 16:05 ET
|
Zafgen, Inc.
BOSTON, March 09, 2017 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by metabolic...
Zafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2016 Financial Results
March 02, 2017 16:05 ET
|
Zafgen, Inc.
BOSTON, March 02, 2017 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by metabolic...
Zafgen to Present at Upcoming Investor Conferences
February 28, 2017 16:05 ET
|
Zafgen, Inc.
BOSTON, Feb. 28, 2017 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by metabolic...
Zafgen to Present at the Leerink Partners 6th Annual Global Healthcare Conference
February 09, 2017 16:05 ET
|
Zafgen, Inc.
BOSTON, Feb. 09, 2017 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by metabolic...
Zafgen Reports Third Quarter 2016 Financial Results
November 09, 2016 16:05 ET
|
Zafgen, Inc.
BOSTON, Nov. 09, 2016 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by metabolic...
Zafgen Initiates Multiple Ascending Dose Cohorts in Phase 1 Clinical Trial of ZGN-1061
September 20, 2016 07:00 ET
|
Zafgen, Inc.
BOSTON, Sept. 20, 2016 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and...
Zafgen Reports Second Quarter 2016 Financial Results
August 04, 2016 16:05 ET
|
Zafgen, Inc.
BOSTON, Aug. 04, 2016 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and...